Bio-Path Holdings is a biotech company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology, which was designed to systemically distribute nucleic acid drugs throughout the human body via intravenous infusion. BPTH is primarily focused on cancer; its lead product candidate, Liposomal Grb-2, is in a phase I study for blood cancers. The company’s second drug candidate is ready for clinical evaluation for lymphoma and solid tumors. For further information, visit the company’s Web site at www.biopathholdings.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: